Related Experiment Video

Updated: Aug 14, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Antiplatelets in stroke prevention: the MATCH trial. Some answers, many questions and countless perspectives

Daniel C Bezerra1, Julien Bogousslavsky

  • 1Department of Neurology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. danielcbezerra@hotmail.com

Cerebrovascular Diseases (Basel, Switzerland)
|December 6, 2005
PubMed

Insights

Combining clopidogrel and aspirin did not improve outcomes for high-risk stroke patients and increased bleeding risk. Future research should identify patient groups who benefit from antiplatelet therapy for secondary stroke prevention.

Area of Science:

  • Neurology
  • Cardiology
  • Pharmacology

Background:

  • Antiplatelet drugs are crucial for secondary stroke prevention.
  • Previous studies (CAPRIE, CURE, CREDO) established their efficacy.
  • High-risk ischemic cerebrovascular patients require optimized treatment strategies.

Purpose of the Study:

  • To evaluate if combining clopidogrel and aspirin is superior to clopidogrel alone.
  • To assess the efficacy of combination therapy in preventing vascular events.
  • To identify optimal antiplatelet strategies for secondary stroke prevention.

Main Methods:

  • The MATCH study design.
  • Inclusion of high-risk ischemic cerebrovascular patients.
  • Comparison of combination therapy (clopidogrel + aspirin) versus monotherapy (clopidogrel).

Main Results:

  • Combination therapy did not demonstrate superior efficacy over clopidogrel monotherapy.
  • A significantly higher risk of bleeding was observed in the combination group.
  • The study provides insights into the risk-benefit profile of dual antiplatelet therapy.

Conclusions:

  • Dual antiplatelet therapy with clopidogrel and aspirin is not recommended for this high-risk population due to increased bleeding risk without added benefit.
  • Findings guide future research to define specific patient subgroups who may benefit from dual antiplatelet therapy.
  • Further investigation is needed to refine secondary stroke prevention strategies.

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...